Home Cart Sign in  
Chemical Structure| 1290541-46-6 Chemical Structure| 1290541-46-6

Structure of RAD51 Inhibitor B02
CAS No.: 1290541-46-6

Chemical Structure| 1290541-46-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

B02 is a RAD51 inhibitor with IC50 of 27.4 μM for human RAD51.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RAD51 Inhibitor B02

CAS No. :1290541-46-6
Formula : C22H17N3O
M.W : 339.39
SMILES Code : O=C1N(CC2=CC=CC=C2)C(/C=C/C3=CC=CN=C3)=NC4=C1C=CC=C4
MDL No. :MFCD03294274
InChI Key :GEKDQXSPTHHANP-OUKQBFOZSA-N
Pubchem ID :5738263

Safety of RAD51 Inhibitor B02

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of RAD51 Inhibitor B02

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 20 µM 24 hours B02 treatment significantly enhanced cccDNA synthesis J Virol. 2023 Jan 31;97(1):e0126122.
HepAD38 cells 10 µM 24 hours B02 treatment significantly enhanced intracellular amplification of cccDNA J Virol. 2023 Jan 31;97(1):e0126122.
U251R cells 10 µM 24 hours To investigate the effect of B02 on Rad51 expression, it was found that B02 treatment significantly reduced the nuclear accumulation of Rad51 and increased γ-H2AX expression, indicating that B02 enhanced the radiosensitivity of GBM cells by inhibiting the nuclear translocation of Rad51. Cancers (Basel). 2021 Apr 21;13(9):1998.
T98G cells 10 µM 24 hours To investigate the effect of B02 on Rad51 expression, it was found that B02 treatment significantly reduced the nuclear accumulation of Rad51 and increased γ-H2AX expression, indicating that B02 enhanced the radiosensitivity of GBM cells by inhibiting the nuclear translocation of Rad51. Cancers (Basel). 2021 Apr 21;13(9):1998.
CHO-K1 cells 1 µg/ml 48 hours To evaluate the cytotoxicity of B02 on CHO-K1 cells and its effect on CRIS-PITCh-mediated integration efficiency. The results showed that B02 treatment improved CRIS-PITCh-mediated integration efficiency by approximately twofold. Sci Rep. 2023 Feb 22;13(1):3116.
Y79 cells 15–20 µM 48 hours B02 caused G2/M arrest, elevated DNA damage, and at higher concentrations (25 µM) induced p53 activation and apoptosis. Oncogene. 2020 Jul;39(31):5338-5357.
RB1021 cells 15–20 µM 48 hours B02 caused G2/M arrest, elevated DNA damage, and at higher concentrations (25 µM) induced p53 activation and apoptosis. Oncogene. 2020 Jul;39(31):5338-5357.
WERI-RB1 cells 15–20 µM 48 hours B02 caused G2/M arrest, elevated DNA damage, and at higher concentrations (25 µM) induced p53 activation and apoptosis. Oncogene. 2020 Jul;39(31):5338-5357.
U-2-OS T-REx (RNH1(D210N)-GFP) cells 20 µM 6 hours To assess the effect of RAD51 inhibition on R-loop formation during early G1 phase, leading to an accumulation of R-loops. Int J Mol Sci. 2021 Apr 3;22(7):3740.
GBM1 cells 1.2 µM B02 reduced RAD51 foci formation and significantly increased the number of γH2AX foci, indicating reduced DNA double-strand break repair capacity. Stem Cell Reports. 2017 Jan 10;8(1):125-139.
GBM4 cells 1.2 µM B02 reduced RAD51 foci formation and significantly increased the number of γH2AX foci, indicating reduced DNA double-strand break repair capacity. Stem Cell Reports. 2017 Jan 10;8(1):125-139.
GBM4UCL cells 1.2 µM B02 reduced RAD51 foci formation and significantly increased the number of γH2AX foci, indicating reduced DNA double-strand break repair capacity. Stem Cell Reports. 2017 Jan 10;8(1):125-139.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice NOD SCID mice Intraperitoneal injection 25 mg/kg Twice per week To assess sensitivity to temozolomide in tumor growth. Oncoimmunology. 2024 Mar 20;13(1):2327682
NOD-Scid mice Orthotopic retinoblastoma xenograft model Intravitreal injection 30 µg Single injection, lasting 7 days B02 significantly inhibited the growth of Y79, RB1021, and WERI-RB1 tumors, reduced cell division, and increased apoptosis without affecting retinal morphology. Oncogene. 2020 Jul;39(31):5338-5357.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.95mL

0.59mL

0.29mL

14.73mL

2.95mL

1.47mL

29.46mL

5.89mL

2.95mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories